Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jan 1;5(3):65-83.
doi: 10.3844/ajisp.2009.65.83.

Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer

Christian M Capitini  1 , Terry J Fry, Crystal L Mackall
Affiliations

Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer

Christian M Capitini et al. Am J Immunol. .

Abstract

PROBLEM STATEMENT: The development of a potent vaccine that can help treat tumors resistant to conventional cytotoxic therapies remains elusive. While part of the problem may be that trials have focused on patients with bulky residual disease, the desire to maximize responses to the vaccine remains. APPROACH: The gamma(c) family of cytokines offer a unique opportunity to support the expansion and effector potential of vaccine-responding T-cells, as well as stimulate other effectors, such as natural killer (NK) cells, to become activated. RESULTS: Combining vaccines with cytokines seems logical but can bring unwanted toxicity, as has been observed with interleukin (IL)-2. In addition, the nonspecific activation or expansion of unwanted cell subsets, such as regulatory T-cells, can contribute to global immunosuppression and limit vaccine responses. The development of IL-7 and IL-21 for the clinic offers the promise of enhancing anti-tumor responses but with far less systemic toxicity and no expansion of regulatory T cells. Preclinical studies demonstrate that IL-15 could also improve T-cell, and especially NK-cell, responses as well. CONCLUSIONS/RECOMMENDATIONS: Future work should expand the use of vaccines with IL-7, IL-21 and hopefully IL-15 in high-risk patients, and consider treatment while in a state of minimal residual disease to maximize benefit. Identifying tumors that can signal through gamma(c) cytokines will also be essential so that induction of relapse will be avoided.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

Figure 1
Figure 1. Target lymphocyte populations of gamma(c) cytokines
While there is considerable overlap of cytokine activity on lymphocytes, effects can be stimulatory or inhibitory depending on the cytokine. IL-21 only increases proliferation of T cells stimulated with anti-CD3 or antigen, but can augment responses to other gamma(c) cytokines. IL-7 acts on developing B cells but not mature cells of this lineage. IL = interleukin, NK = natural killer, NKT = natural killer-T cell, Treg = regulatory T cell
See this image and copyright information in PMC

References

    1. Fehniger TA, Cooper MA, Caligiuri MA. Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine & Growth Factor Reviews. 2002;13:169–183. - PubMed
    1. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nature Reviews of Immunology. 2006;6:595–601. - PubMed
    1. Zhang H, Chua KS, Guimond M, et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med. 2005;11:1238–1243. - PubMed
    1. Chapman PB. Combining a peptide vaccine with high-dose interleukin-2. J Clin Oncol. 2008;26:2250–2251. - PubMed
    1. Coppin C. Immunotherapy for renal cell cancer in the era of targeted therapy. Expert Review of Anticancer Therapy. 2008;8:907–919. - PubMed

LinkOut - more resources